文献速递眼底病与葡萄膜炎

姜黄类营养补充剂与年龄相关性黄斑变性风险

Curcuma-Based Nutritional Supplements and Risk of Age-Related Macular Degeneration.
PubMed 文献 · JAMA Ophthalmol · 2024-01-01

这项回顾性队列研究利用TriNetX电子健康记录网络数据,比较使用与未使用姜黄类营养补充剂(CBNS)患者发生或进展年龄相关性黄斑变性(AMD)的风险。在无AMD史且年龄≥50岁患者中,CBNS使用与发生非渗出性AMD、晚期非渗出性AMD或地图样萎缩、渗出性AMD、失明及需玻璃体内抗VEGF治疗的风险降低相关;在早期非渗出性AMD患者中,CBNS使用与进展为晚期非渗出性AMD或地图样萎缩的风险降低相关。作者建议进一步研究验证这些发现、安全性及潜在药理保护机制。

要点

  • 无AMD史且≥50岁者中,CBNS使用与发生非渗出性AMD风险降低相关(RR 0.23)。
  • 无AMD史且≥50岁者中,CBNS使用与需玻璃体内抗VEGF治疗风险降低相关(RR 0.15)。
  • 早期非渗出性AMD患者中,CBNS使用与进展为晚期非渗出性AMD或地图样萎缩风险降低相关(RR 0.58)。

核心结论

  • 这项队列研究结果提示,后续使用CBNS与发生AMD或进展至AMD较晚期阶段的风险降低相关。
  • 作者建议进一步研究以验证这些发现、安全性及CBNS在AMD中的潜在药理保护机制。

研究设计与样本

  • 这是一项回顾性队列研究,数据收集于2024年6月,数据来自聚合电子健康记录研究网络TriNetX(马萨诸塞州剑桥)。
  • 研究纳入无AMD史且使用与不使用CBNS的患者,按CBNS处方记录分层,并进行倾向评分匹配以控制基线人口学和医学合并症。
  • 研究还识别有早期非渗出性AMD史的患者,并按CBNS处方记录分层。
  • 暴露按是否使用CBNS通过RxNorm(美国国家医学图书馆)代码进行分层。
  • 使用CBNS组共66804例(平均[SD]年龄64.9[10.1]岁;女性44124例[66.1%]),不使用CBNS组共1809440例(平均[SD]年龄67.0[9.5]岁;女性999534例[55.2%])。

主要发现

  • 在无AMD史且年龄≥50岁患者中,与匹配的不使用CBNS患者相比,CBNS使用与发生非渗出性AMD风险降低相关(RR 0.23;95%CI 0.21-0.26;P<.001)。
  • 在无AMD史且年龄≥50岁患者中,与匹配的不使用CBNS患者相比,CBNS使用与发生晚期非渗出性AMD或地图样萎缩风险降低相关(RR 0.11;95%CI 0.07-0.17;P<.001)。
  • 在无AMD史且年龄≥50岁患者中,与匹配的不使用CBNS患者相比,CBNS使用与发生渗出性AMD风险降低相关(RR 0.28;95%CI 0.24-0.32;P<.001)。
  • 在无AMD史且年龄≥50岁患者中,与匹配的不使用CBNS患者相比,CBNS使用与发生失明风险降低相关(RR 0.46;95%CI 0.36-0.59;P<.001),与需玻璃体内抗VEGF治疗风险降低相关(RR 0.15;95%CI 0.13-0.17;P<.001)。
  • 在早期非渗出性AMD患者中,与无CBNS处方记录的匹配患者相比,后续CBNS处方记录与发生晚期非渗出性AMD或地图样萎缩风险降低相关(RR 0.58;95%CI 0.41-0.81;P<.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者建议进一步研究以验证这些发现、安全性及CBNS在AMD中的潜在药理保护机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Curcuma-based nutritional supplements (CBNS) are natural anti-inflammatory and antioxidant agents that may confer benefits against age-related macular degeneration (AMD). OBJECTIVE: To examine the association between the use of CBNS and the risk of development or progression of AMD. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective cohort study with data collection in June of 2024. Data were gathered from the aggregated electronic health records research network, TriNetX (Cambridge, Massachusetts). Patients without AMD were included in the study before propensity score matching (PSM); these included those taking and not taking CBNS. Patients with no history of AMD were stratified by instances of CBNS prescription records. Patients with a history of early nonexudative AMD stratified by instances of CBNS prescription records were also identified. PSM was performed to control for baseline demographics and medical comorbidities. EXPOSURES: Patients were stratified by whether or not they were taking CBNS using RxNorm (National Library of Medicine) codes. MAIN OUTCOME MEASURES: Relative risk (RR) of developing nonexudative AMD, exudative AMD, advanced nonexudative AMD or geographic atrophy (GA), blindness, or requiring intravitreal anti-vascular endothelial growth factor (VEGF) therapy. RESULTS: A total of 66 804 patients (mean [SD] age, 64.9 [10.1] years; 44 124 female [66.1%]) taking CBNS and 1 809 440 patients (mean [SD] age, 67.0 [9.5] years; 999 534 female [55.2%]) not taking CBNS were included in this study. Among patients without a history of AMD aged 50 years or older, CBNS use was associated with lower rates of developing nonexudative AMD (RR, 0.23; 95% CI, 0.21-0.26; P < .001), advanced nonexudative AMD or GA (RR, 0.11; 95% CI, 0.07-0.17; P < .001), exudative AMD (RR, 0.28; 95% CI, 0.24-0.32; P < .001), blindness (RR, 0.46; 95% CI, 0.36-0.59; P < .001), or requiring intravitreal anti-VEGF therapy (RR, 0.15; 95% CI, 0.13-0.17; P < .001) when compared with matched patients not taking CBNS. Results were consistent among subsets of patients 60 and 70 years or older, respectively. Among patients with early nonexudative AMD, subsequent instances of CBNS prescription records were associated with lower rates of developing advanced nonexudative AMD or GA (RR, 0.58; 95% CI, 0.41-0.81; P < .001) when compared with matched patients with early nonexudative AMD without a CBNS prescription record. CONCLUSION AND RELEVANCE: Results of this cohort study suggest that a reduced risk of developing AMD or progression to later stages of AMD was associated with subsequent use of CBNS. Further investigation to validate these findings, safety, and potential pharmacoprotective mechanisms of CBNS in AMD are suggested.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Alsoudi AF, Wai KM, Koo E, et al. Curcuma-Based Nutritional Supplements and Risk of Age-Related Macular Degeneration. JAMA Ophthalmol. 2024. PMID: 39446346. doi:10.1001/jamaophthalmol.2024.4400

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。